AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$PRGO

Perrigo to sell infant formula business to MeridianMade for $175M

Perrigo (PRGO) agreed to sell its infant formula business to MeridianMade for up to $175M. The deal includes $40M in cash upfront and up to $135M in performance-based payments through 2030.

Original reporting
seekingalpha.com
Published Oct 29, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$PRGO
Bullish
high confidence
Mentioned
$PRGO
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PRGOBullishMed
01

Why it matters

The transaction is a portfolio change that can affect PRGO’s earnings mix, cash generation profile, and investor perception of strategic focus.

02

Market read

Signed divestiture terms with explicit upfront and total consideration are likely to drive near-term repricing of PRGO’s valuation and segment outlook.

03

What to watch

Traders may need details on the divestiture’s impact on guidance, tax treatment, and whether PRGO retains any manufacturing, distribution, or brand rights post-sale.

Relevance 9/10Novelty 8/10Timing: deal announced today

Background

Perrigo is selling its infant formula business to MeridianMade under a consideration structure split between upfront cash and performance-based payments through 2030.

Company-level read

Ticker impact

$PRGOBullishHigh confidence
Context

Perrigo agreed to sell its infant formula business to MeridianMade for $40M upfront and up to $175M total through 2030 milestones.

Expected impact

Likely modest positive reaction as investors price in upfront cash and milestone-driven proceeds, offset by any earnings impact from divesting the unit.

Evidence & confidence

The article discloses a specific, signed divestiture with defined cash upfront and total consideration, which is typically valuation-relevant for the seller.

Market effects

Sector

Could be read-across for infant formula supply chain and brand portfolio reshuffling among consumer health and nutrition peers.

Regional

Limited direct regional impact implied; transaction is company-specific.

Global

Moderate global relevance via potential changes in infant formula competitive landscape and supply ownership.

Counterpoint

What could challenge this read

The headline total value may not translate into near-term earnings power if milestone conditions are hard to achieve or if the divested business had higher margins than the rest of PRGO.

Key entities

  • company
    Perrigo Company plc

    Seller of the infant formula business; ticker PRGO.

  • company
    MeridianMade

    Buyer of Perrigo’s infant formula business.

Read at source← All news

StoryPerrigo to sell its infant formula business to MeridianMade for up to $175 million

Also covered by

3 outlets

Related articles

$PRGOMed

Perrigo Q3 Earnings Call Highlights

Perrigo (PRGO) reported Q3 earnings with net sales declines in self-care and specialty care segments. Adjusted EPS fell to 61 cents, with a lower tax rate providing some benefit. The company expects 2026 sales declines and adjusted EPS of $2.15-$2.35. Perrigo is divesting infant formula and other businesses to simplify operations and reduce debt. Cash and debt at quarter-end were $437M and $3.3B, respectively.

finance.yahoo.com
$PRGOHigh

Perrigo Sets 2026 All-In Adjusted EPS Outlook at $2.25 to $2.45

Perrigo Company plc set its 2026 adjusted diluted EPS outlook at $2.25 to $2.45, excluding its infant formula unit, which it classified as discontinued operations. Core EPS is expected at $2.15 to $2.35, with core sales declining 2.5% to 3.6% and an adjusted operating margin of 14% to 15%. The company plans to sell the unit to MeridianMade for up to $175 million, with $40 million upfront.

tokenpost.com
$PRGOMed

Perrigo Co PLC (PRGO) (Q3 2026) Earnings Call Highlights: Margin Gains and Share Growth

Perrigo (PRGO) reported Q3 2026 core net sales declined 1.7% YoY, with organic sales down 1.1%. Adjusted gross margin fell 140 bps to 37.9%. The company updated its 2026 outlook downward, citing retailer inventory positioning and European softness. Interim CEO Albert Manzone highlighted share gains, innovation, and e-commerce growth as priorities. The infant formula divestiture is complete, and oral care is under strategic review.

finance.yahoo.com
$PRGOMed

Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo (PRGO) reported Q3 2026 earnings, highlighting operational improvements and a strategic focus on simplifying the business. The company saw sequential improvements in core net sales and operating margins, with a 1.7% decline in sales and a 14.3% operating margin. Perrigo announced the sale of its infant formula business and updated its 2026 outlook, reflecting divestments and market conditions.

finance.yahoo.com
$PRGOMed

Perrigo Company plc Q3 2026 Earnings Call Summary

Perrigo reported Q3 2026 improvements in core adjusted operating margins (12.8% to 14.3%) due to its Three-S plan. The company is simplifying its portfolio, including divesting the infant formula business, to focus on higher-margin categories. Market share gains in U.S. and European OTC brands were noted, along with e-commerce expansion. Management updated 2026 and 2027 outlooks, emphasizing debt reduction and operational improvements. Q3 results included a $4.5M one-time tariff benefit.

finance.yahoo.com